Recombinant Rabbit monoclonal primary
Recombinant S100A4 Monoclonal Antibody (ET1612-13)
NIH/3T3, MCF-7, Hela, human tonsil tissue, mouse lung tissue, human lung tissue, human gastric carcinoma tissue.
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A affinity purified.
18A2 antibody; 42A antibody; calcium Placental protein antibody; Calvasculin antibody; CAPL antibody; Fibroblast specific protein 1 (FSP1) antibody; Fibroblast specific protein 1 antibody; Fibroblast specific protein antibody; FSP1 antibody; Leukemia multidrug resistance associated protein antibody; Malignant transformation suppression 1 (MTS1) antibody; Malignant transformation suppression 1 antibody; Metastasin antibody; MTS1 antibody; OTTHUMP00000015467 antibody; OTTHUMP00000015468 antibody; P9KA antibody; PEL98 antibody; Placental calcium-binding protein antibody; Protein Mts1 antibody; Protein S100 A4 antibody; Protein S100-A4 antibody; S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog) antibody; S100 calcium binding protein A4 antibody; S100 calcium-binding protein A4 antibody; S100a4 antibody; S10A4_HUMAN antibody
Belongs to the S-100 family.
Extracellular space, nucleus.
The Mts1 gene encodes a small acidic Ca2+-binding protein, Mts1 (also designated S100A4, calvasculin or metastasin). Mts1 belongs to the S100 family of small Ca2+-binding proteins and is expressed in a cell-specific manner. Mts1 protein is involved in tumor progression and metastasis, and also has a significant stimulatory effect on angiogenesis. The level of Mts1 protein in serum increases with aging, suggesting that Mts1 may play a role in the ind-uction of tumor progression via stimulation of angiogenesis. In addition, Mts1 cooperates with p53 in apoptosis induction by binding to the C-term-inal regulatory domain of p53 to inhibit the DNA binding activity of p53. The ability of Mts1 to enhance p53-dependent apoptosis may accelerate the loss of p53 function in tumors. Thus, Mts1 can contribute to the development of a more aggressive phenotype during tumor progression.